Xeroderma Pigmentosum: an Insight Into DNA Repair Processes

Xeroderma Pigmentosum: an Insight Into DNA Repair Processes

ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner have, or have had, within the past 12 months, which relates to the content of this educational activity and creates a conflict of interest. Dr. Jennifer O. Black declares she has no conflict(s) of interest to disclose. Xeroderma Pigmentosum: An Insight into DNA Repair Processes Jennifer O. Black, MD Assistant Professor Division of Pediatric Pathology and Laboratory Medicine Children’s Hospital Colorado University of Colorado Anschutz Medical Campus Aurora, Colorado Introduction: Xeroderma Pigmentosum Xeroderma Pigmentosum (XP): • Initially described 1874 • Rare autosomal recessive disorder • Prevalence: 1-45/million, variable ethnic frequency • UV radiation sensitivity disorder characterized by: • Severe skin burning following minimal sun exposure • Early freckling (before 2 years of age) • Skin cancer at an early age Kraemer KH, DiGiovann JJ. Photochemistry and Photobiology 91:452-459, 2015 Introduction: Xeroderma Pigmentosum XP Clinical Spectrum: • Skin Changes: o Early freckling and subsequent checkered pigmentation o Thin, dry, contracted skin o Telangiectasias o Skin cancers: o Squamous cell carcinoma o Basal cell carcinoma o Melanoma Courtesy Dr. Bahig M. Shehata, Children’s Healthcare of Atlanta Introduction: Xeroderma Pigmentosum Squamous Cell Carcinoma Robbins and Cotran Pathologic Basis of Disease. Lazar, Alexander J.F.; Murphy, George F. Pages 1141-1178 Introduction: Xeroderma Pigmentosum Basal Cell Carcinoma Robbins and Cotran Pathologic Basis of Disease. Lazar, Alexander J.F.; Murphy, George F. Pages 1141-1178. Introduction: Xeroderma Pigmentosum Melanoma Pigment Cell & Melanoma Research Volume 27, Issue 3, pages 454-464 Introduction: Xeroderma Pigmentosum Ocular Manifestations of Disease OCULAR ABNORMALITIES Structural Eyelid Abnormalities: Entropion Ectropion* Lagophthalmos Blepharitis Keratinization Loss of Eyelashes Neoplasms of the Ocular Surface Squamous Cell Carcinoma and Eyelids: Basal Cell Carcinoma Ocular Surface Disease and Conjunctivitis Inflammation: Melanosis* Xerosis Corneal Abnormalities: Neovascularization Pterygium Scarring Brooks et al. Ophthalmology. 2013 Jul; 120(7): 1324–1336. Opacification Other: Photophobia * More frequent in patients with non-burning phenotype Introduction: Xeroderma Pigmentosum Neurologic Manifestations of Disease • 24% XP Patients • Progressive Neurologic Degeneration: o Cognitive deterioration o Impaired hearing o Abnormal speech o Areflexia o Progressive ataxia o Spasticity o Peripheral neuropathy • Brain tumors: Glial tumors • Pontine glioma, glioblastoma, spinal cord astrocytoma Anttinen, et al. Brain. 2008 Aug;131:1979-89 Xeroderma Pigmentosum: Disease Pathophysiology Xeroderma Pigmentosum: Pathophysiology BER: Base excision repair NER: Nucleotide excision repair DSBR: Double stranded break repair MMR: Mismatch repair Xeroderma Pigmentosum: Pathophysiology Historical Studies: • XP cells demonstrate UV radiation hypersensitivity (Gartler 1964) • Deficient excision repair observed in cultured XP skin fibroblasts (Cleaver 1968) • Stable DNA photoproducts identified following UV radiation (Setlow 1962), not removed by XP cells ( Setlow 1969, Cleaver and Trosko 1970) • Defective excision repair in XP cells demonstrated in vitro (Reed 1969) and in vivo (Epstein 1970) • Cell fusion studies demonstrated heterogeneity of XP molecular defects ( De Weerd-Kastelein 1972) Fusion of fibroblasts from different XP patients form heterokaryons that demonstrate corrected DNA repair mechanisms. Characterization of different complementation groups, A-G (Kramer 1975, Arase 1979, Keijer 1979) Xeroderma Pigmentosum: Complementation Groups Complementation Gene Normal Protein Function Disease Characteristics Group Protein that assists with DNA unwinding Photosensitivity, poikiloderma, lentigines, skin cancer, XP-A XPA neurodegeneration Helicase involved with DNA unwinding Photosensitivity, poikiloderma, lentigines, skin cancer, XP-B XPB/ERCC3 neurodegeneration XP-C XPC Protein recognizing global genome defects Photosensitivity, poikiloderma, lentigines, skin cancer Helicase involved with DNA unwinding Photosensitivity, poikiloderma, lentigines, skin cancer, XP-D XPD/ERCC2 neurodegeneration, brain tumors Protein recognizing global genome defects Photosensitivity, poikiloderma, lentigines, skin cancer, XP-E XPE/DDB2 neurodegeneration Forms an endonuclease together with ERCC1 that Photosensitivity, poikiloderma, lentigines, skin cancer, XP-F XPF/ERCC4 incises damaged DNA for repair neurodegeneration, brain tumors Endonuclease that incise damaged DNA Photosensitivity, poikiloderma, lentigines, skin cancer, XP-G XPG/ERCC5 neurodegeneration DNA-polymerase eta (pol-eta) which performs Milder photosensitivity and poikiloderma XP-Variant XPV/POLH trans-lesion DNA synthesis past ultraviolet (UV) Xeroderma Pigmentosum: Pathophysiology Nucleotide Excision Repair Pathway DiGiovanna. J Invest Dermatol. 2012 Mar; 132(3): 785–796. Xeroderma Pigmentosum: Pathophysiology DiGiovanna. J Invest Dermatol. 2012 Mar; 132(3): 785–796. Xeroderma Pigmentosum: Overlap Syndromes Gene Normal Protein Function Clinical Syndrome Disease Characteristics XPB/ERCC3 Helicase involved with DNA unwinding XP-B, CS, TTD Photosensitivity, poikiloderma, lentigines, skin cancer, neurodegeneration XPD/ERCC2 Helicase involved with DNA unwinding XP-D, TTD, COFS, CS Photosensitivity, poikiloderma, lentigines, skin cancer, neurodegeneration, brain tumors XPF/ERCC4 Forms an endonuclease together with ERCC1 that incises XP-F, XFE progeroid Photosensitivity, poikiloderma, lentigines, skin cancer, damaged DNA for repair syndrome, Fanconi anemia neurodegeneration, brain tumors ERCC1 Forms an endonuclease together with XPF/ERCC4 that XP, CS, COFS Photosensitivity, poikiloderma, lentigines, skin cancer, incises damaged DNA for repair neurodegeneration CSA/ERCC8 DNA excision repair protein involved in the TCR pathways CS Growth failure, impaired neurodevelopment, photosensitivity, eye disorders, premature aging CSB/ERCC6 DNA excision repair protein involved in the TCR pathway CS, COFS Growth failure, severely impaired neurodevelopment, photosensitivity, eye disorders, premature aging GTF2H5 TTDA protein stabilizes the DNA/protein complex during TTD Brittle hair, intellectual impairment, photosensitivity unwinding of DNA strand for repair TTDN1/C7orf11 Regulates mitosis and cytokinesis TTD Non-photosensitive TTD CS = Cockayne Syndrome; TTD = Trichothiodystrophy; COFS = Cerebro-Oculo-Facio-Skeletal Syndrome Xeroderma Pigmentosum: Overlap Syndromes Trichothiodystrophy (TTD): • Features: • Photosensitivity (with XPD, XPB, TTDA but not TTDN1 mutations) • Abnormal hair • Decreased fertility • Short stature • Ichthyosis • Normal skin pigmentation • Intellectual impairment without neurodegeneration • Neuroimaging: demyelination, cortical heterotopia, partial agenesis of the corpus callosum, perimedullary fibrosis of the spinal cord, intracranial calcifications DiGiovanna. J Invest Dermatol. 2012 Mar; 132(3): 785–796. Xeroderma Pigmentosum: Overlap Syndromes Cockayne Syndrome (CS) • Results from mutations in the CSA and CSB genes of the NER pathway • Features: • Short stature • Microcephaly • Pigmentary retinal degeneration • Kyphoscoliosis • Gait defects • Sensorineural deafness • Distinct facial features (deep-set eyes, prominent ears, “wizened appearance”) • Neurodegenerative Features; Demyelination (increased DTRs), • Neuroimaging: cerebral atrophy, ventricular dilation, calcification of basal ganglia and cortex, neuronal loss • Multiple Types: • Type I: moderate phenotype, normal prenatal development, abnormalities evident in first 2 years of life • Type II: Severe phenotype, growth failure at birth, death first decade • Type III: Mild symptoms, late onset; photosensitivity with normal pigmentation, no increased risk of cutaneous malignancy Laugel. Mechanisms of Ageing and Development 134 (2013) 161–170 Xeroderma Pigmentosum: Overlap Syndromes Cerebro-Oculo-Facio-Skeletal Syndrome (COFS): • Autosomal recessive disorder\ • Mutations involve CSB, XPD, XPG, and ERCC1 genes • Features: • Microcephaly • Congenital cataracts • Arthrogryposis • Severe developmental delay • Severe postnatal growth failure • Photosensitivity • Facial dysmorphism (prominent nasal root and overhanging upper lip) Laugel. J Med Genet 2008;45:564-571 Xeroderma Pigmentosum Disease Course Xeroderma Pigmentosum: Long Term Survival Leading Cause of Death: Skin cancer and metastasis Lifetime Cancer Risk: • 33% XP patients do not develop cancer • Squamous Cell and Basal Cell Carcinoma: o Median age at first cancer = 9 years (range 1-32 years) o XP patients have 58-year reduction in age at first non-melanocytic skin cancer o 10,000 fold lifetime risk compared to general population • Melanoma: o Median age at first cancer = 22 years (range 2-47 years) o XP patients have a 33-year reduction in age at first non-melanocytic skin cancer o 2,000 fold lifetime risk compared to general population o PTEN mutations more common (53%) compared to general population (16%) • Other Cancer: • Increased risk of lung cancer in XP smokers • Brain tumors Neurodegeneration: • More common in XPA, XPB, XPD, XPF, XPG (Rare in XPC, XPE) • Associated with decreased median age of death compared to XP patients without neurodegeneration (29 vs 37 years) • Second leading cause of death in XP patients

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    26 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us